Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Juvenile Nonclinical Safety Studies in Support of Pediatric Drug Development.

Methods in molecular biology (Clifton, N.J.)·2017
Same author

The teratology testing of food additives.

Methods in molecular biology (Clifton, N.J.)·2012
Same author

Developmental toxicity testing of vaccines.

Methods in molecular biology (Clifton, N.J.)·2012
Same author

The teratology testing of cosmetics.

Methods in molecular biology (Clifton, N.J.)·2012
Same author

Reporting of teratology studies.

Methods in molecular biology (Clifton, N.J.)·2012
Same author

Preclinical evaluation of juvenile toxicity.

Methods in molecular biology (Clifton, N.J.)·2010

Related Experiment Video

Updated: Jun 21, 2026

Toxicity Screens in Human Retinal Organoids for Pharmaceutical Discovery
07:45

Toxicity Screens in Human Retinal Organoids for Pharmaceutical Discovery

Published on: March 4, 2021

Reproductive toxicity testing for pharmaceuticals under ICH.

Paul C Barrow1

  • 1MDS Pharma Services, 329 Impasse du Domaine Rozier, Les Oncins, 69210 Saint-Germain sur l'Arbresle, France. paul.barrow@mdsinc.com

Reproductive Toxicology (Elmsford, N.Y.)
|July 28, 2009
PubMed
Summary
This summary is machine-generated.

Drug reproductive toxicity testing faces challenges with limited species and preliminary study designs. Enhancing methods like double staining and imaging can improve teratogenicity screening and hazard detection.

More Related Videos

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation
17:28

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Published on: June 17, 2015

Rapid Evaluation of Toxicity of Chemical Compounds Using Zebrafish Embryos
07:49

Rapid Evaluation of Toxicity of Chemical Compounds Using Zebrafish Embryos

Published on: August 25, 2019

Related Experiment Videos

Last Updated: Jun 21, 2026

Toxicity Screens in Human Retinal Organoids for Pharmaceutical Discovery
07:45

Toxicity Screens in Human Retinal Organoids for Pharmaceutical Discovery

Published on: March 4, 2021

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation
17:28

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Published on: June 17, 2015

Rapid Evaluation of Toxicity of Chemical Compounds Using Zebrafish Embryos
07:49

Rapid Evaluation of Toxicity of Chemical Compounds Using Zebrafish Embryos

Published on: August 25, 2019

Area of Science:

  • Pharmacology and Toxicology
  • Developmental Biology
  • Drug Safety Assessment

Background:

  • Current drug reproductive toxicity testing relies on a limited number of animal species (rat, rabbit, mouse, minipig).
  • Existing protocols, including proposed ICH M3 guideline revisions, present challenges in accurately assessing teratogenicity and reproductive hazards.
  • Preliminary embryotoxicity studies with small sample sizes raise concerns about reliability.

Purpose of the Study:

  • To evaluate the limitations of current drug reproductive toxicity testing methodologies.
  • To identify potential improvements for enhanced screening of teratogenicity and reproductive hazards.
  • To suggest advancements for future revisions of reproductive toxicity guidelines.

Main Methods:

  • Review of standard reproductive toxicity testing packages (2- or 3-segment).
  • Analysis of species selection limitations for small molecule drug testing.
  • Exploration of established chemical testing methods (e.g., double fetus staining, primordial follicle counts) and modern imaging techniques for application in drug development.

Main Results:

  • The limited species selection poses a significant threat to effective teratogenicity screening.
  • Proposed guideline revisions may not sufficiently address confidence in preliminary embryotoxicity study results.
  • Methods like double staining, follicle counts, and advanced imaging offer potential to improve hazard detection.

Conclusions:

  • Improving drug reproductive toxicity testing requires expanding species options and refining study designs.
  • Incorporating established chemical testing methods and modern imaging can enhance the detection of developmental and reproductive hazards.
  • Future guidelines should consider including developmental immunotoxicity assessments.